We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Abevmy 100 and 400 mg is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer, non small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen.
Biocon Biologics, a subsidiary of Biocon announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authoris ation of their biosimilar Bevacizumab ...